DOUBLE-EXPRESSOR LYMPHOMA
Clinical trials for DOUBLE-EXPRESSOR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DOUBLE-EXPRESSOR LYMPHOMA trials appear
Sign up with your email to follow new studies for DOUBLE-EXPRESSOR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets tough lymphoma in early trial
Disease control Recruiting nowThis study tests a new drug called pidnarulex (CX-5461) in 50 people with aggressive B-cell lymphomas that have MYC gene changes. The goal is to find a safe dose and see if it can shrink tumors. Participants have already tried other treatments and have limited options.
Matched conditions: DOUBLE-EXPRESSOR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for aggressive lymphoma: targeted therapy before chemo shows promise
Disease control Recruiting nowThis study tests a two-step treatment for people with a fast-growing type of lymphoma that is hard to treat. First, a targeted drug (loncastuximab tesirine) plus rituximab is given to attack cancer cells directly. Then, standard chemotherapy (DA-EPOCH-R) is used to kill remaining…
Matched conditions: DOUBLE-EXPRESSOR LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 11, 2026 20:52 UTC